16 reports

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Cancer Hormonal Therapy
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Beijing Novartis Pharma Ltd

THE MOST COMMON GRADE ##-## ADVERSE EVENTS INCLUDED NEUTROPENIA (##%), HYPOKALEMIA (##%), HYPOPHOSPHATEMIA (##%), RASH (##%), TUMOR FLARE (##%) AND GASTROINTESTINAL COMPLAINTS (##%).

  • Cancer Hormonal Therapy
  • Targeted Therapy
  • United States
  • Demand
  • Celgene Corporation

OPROZOMIB IS ASSOCIATED WITH GASTROINTESTINAL TOXICITIES, WITH THE MOST COMMON GRADE ## AES BEING DIARRHEA, NAUSEA, AND VOMITING.

  • Cancer Hormonal Therapy
  • Market Size
  • Celgene Corporation
  • Janssen Biotech, Inc.
  • Novartis AG

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • Janssen Biotech, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • Janssen Biotech, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • National Comprehensive Cancer Network, Inc.
  • Novartis AG
  • PharmaMar SA
  • Takeda Pharmaceutical Company Limited

Oprozomib is associated with gastrointestinal toxicities, with the most common Grade ## AEs being diarrhea, nausea, and vomiting.

  • Cancer Hormonal Therapy
  • United States
  • National Comprehensive Cancer Network, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

Common toxicities were hematological and gastrointestinal.

  • Cancer Hormonal Therapy
  • Oncology
  • United States
  • World
  • Acetylon Pharmaceuticals, Inc.

Gastrointestinal-related AEs were infrequent and low grade.

  • Cancer Hormonal Therapy
  • Pharmaceutical
  • Therapy
  • United States
  • Karyopharm Therapeutics Inc.

DLTs were Gr## asthenia (n = ##) and Gr## mood altered (n = ##) at ## mg; and Gr## neutropenia (n = ##) and Gr## and Gr## hyperglycemia (n = ## each) at ## mg.

  • Cancer Hormonal Therapy
  • Pathology
  • Therapy
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Cancer Hormonal Therapy
  • Clinical Trial
  • Oncology
  • World
  • Celgene Corporation

The prominent features of this report are - ##.

  • Cancer Hormonal Therapy
  • Endocrine Disease
  • Monoclonal Antibody
  • World
  • Product Initiative

Gastrointestinal adverse events were generally manageable with antiemetics.

  • Cancer
  • Cancer Hormonal Therapy
  • United States
  • Product Initiative
  • Karyopharm Therapeutics Inc.

A single infusion of CAEL-## or one weekly infusion for four weeks have demonstrated early and sustained organ response in cardiac, renal, gastrointestinal, skin and soft tissue.

  • Cancer Hormonal Therapy
  • Clinical Trial
  • Drug Discovery And Development
  • World
  • Product Initiative
  • Clinical Trial Profile Snapshots

(Inactive) ## AXIS Clinicals Limited ## Bluefish Pharmaceuticals AB ## F.

  • Breast Cancer
  • Cancer Hormonal Therapy
  • Hormone
  • World
  • Product Initiative
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Cancer Hormonal Therapy
  • Oncology
  • Therapy
  • World
  • Product Initiative